

**Amendments to the Claims:**

Please amend claim 2 as set forth below.

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Canceled)
2. (Currently Amended) A method of detecting expression of growth differentiation factor-5 (GDF-5) in a tissue specimen of a subject, comprising contacting an antibody that specifically binds a GDF-5 polypeptide having an amino acid sequence as set forth in SEQ ID NO:10 or SEQ ID NO:13, or an antigen binding fragment of the antibody, with a tissue specimen of the subject, and detecting binding of the antibody or the antigen binding fragment of the antibody, ~~wherein an increased or decreased level of binding to the tissue specimen as compared to binding to normal cells is indicative of altered expression of the GDF-5 polypeptide in the subject, and~~ wherein the specimen is from uterine neoplasm tissue or ~~or~~ skeletal tissue.
3. (Canceled)
4. (Canceled)
5. (Previously Presented) The method of claim 2, wherein the detecting is *in vivo*.
6. (Previously Presented) The method of claim 2, wherein the detection is *in vitro*.
7. (Previously Presented) The method of claim 2, wherein the antibody is detectably labeled.

8. (Previously Presented) The method of claim 7, wherein the detectable label is a radioisotope, a fluorescent compound, a bioluminescent compound, a chemiluminescent compound, an enzyme, a colloidal metal, a phosphorescent compound, or a paramagnetic isotope.

9. (Withdrawn) The method of claim 2, wherein the antibody comprises a hapten coupled thereto.

10. (Withdrawn) The method of claim 9, wherein the hapten is biotin, dinitrophenyl, puridoxal, or fluorescein.

11. (Previously Presented) The method of claim 2, wherein the antibody is a monoclonal antibody.

12. (Previously Presented) The method of claim 2, wherein the antigen binding fragment of the antibody is a Fab fragment or an F(ab')<sub>2</sub> fragment.

13. (Withdrawn) The method of claim 2, wherein the antibody or antigen binding fragment of the antibody is bound to a solid phase carrier.

14. (Withdrawn) The method of claim 13, wherein the solid phase carrier comprises glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylase, natural cellulose, modified cellulose, polyacrylamide, agarose or magnetite.